These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
181 related articles for article (PubMed ID: 36724301)
1. Efficacy, Safety, and Satisfaction with the Accu-Chek Insight with Diabeloop Closed-Loop System in Subjects with Type 1 Diabetes: A Multicenter Real-World Study. Chico A; Navas de Solís S; Lainez M; Rius F; Cuesta M Diabetes Technol Ther; 2023 Apr; 25(4):242-249. PubMed ID: 36724301 [No Abstract] [Full Text] [Related]
2. Diabeloop DBLG1 Closed-Loop System Enables Patients With Type 1 Diabetes to Significantly Improve Their Glycemic Control in Real-Life Situations Without Serious Adverse Events: 6-Month Follow-up. Amadou C; Franc S; Benhamou PY; Lablanche S; Huneker E; Charpentier G; Penfornis A; Diabetes Care; 2021 Mar; 44(3):844-846. PubMed ID: 33431420 [TBL] [Abstract][Full Text] [Related]
3. Closed-loop insulin delivery in adults with type 1 diabetes in real-life conditions: a 12-week multicentre, open-label randomised controlled crossover trial. Benhamou PY; Franc S; Reznik Y; Thivolet C; Schaepelynck P; Renard E; Guerci B; Chaillous L; Lukas-Croisier C; Jeandidier N; Hanaire H; Borot S; Doron M; Jallon P; Xhaard I; Melki V; Meyer L; Delemer B; Guillouche M; Schoumacker-Ley L; Farret A; Raccah D; Lablanche S; Joubert M; Penfornis A; Charpentier G; Lancet Digit Health; 2019 May; 1(1):e17-e25. PubMed ID: 33323237 [TBL] [Abstract][Full Text] [Related]
4. One-year real-world performance of the DBLG1 closed-loop system: Data from 3706 adult users with type 1 diabetes in Germany. Benhamou PY; Adenis A; Lebbad H; Tourki Y; Heredia MB; Gehr B; Franc S; Charpentier G Diabetes Obes Metab; 2023 Jun; 25(6):1607-1613. PubMed ID: 36751978 [TBL] [Abstract][Full Text] [Related]
5. Utility of time in tight range (TITR) in evaluating metabolic control in pediatric and adult patients with type 1 diabetes in treatment with advanced hybrid closed-loop systems. Bahillo-Curieses P; Fernández Velasco P; Pérez-López P; Vidueira Martínez AM; Nieto de la Marca MO; Díaz-Soto G Endocrine; 2024 Nov; 86(2):539-545. PubMed ID: 38814372 [TBL] [Abstract][Full Text] [Related]
6. Closed-loop insulin delivery in pregnant women with type 1 diabetes (CRISTAL): a multicentre randomized controlled trial - study protocol. Beunen K; Van Wilder N; Ballaux D; Vanhaverbeke G; Taes Y; Aers XP; Nobels F; Marlier J; Lee D; Cuypers J; Preumont V; Siegelaar SE; Painter RC; Laenen A; Gillard P; Mathieu C; Benhalima K BMC Pregnancy Childbirth; 2023 Mar; 23(1):180. PubMed ID: 36927458 [TBL] [Abstract][Full Text] [Related]
7. Glycemic Outcomes During Real-World Hybrid Closed-Loop System Use by Individuals With Type 1 Diabetes in the United States. Arunachalum S; Velado K; Vigersky RA; Cordero TL J Diabetes Sci Technol; 2023 Jul; 17(4):951-958. PubMed ID: 35414272 [TBL] [Abstract][Full Text] [Related]
8. Closed-Loop Insulin Therapy for People With Type 2 Diabetes Treated With an Insulin Pump: A 12-Week Multicenter, Open-Label Randomized, Controlled, Crossover Trial. Borel AL; Lablanche S; Waterlot C; Joffray E; Barra C; Arnol N; Amougay H; Benhamou PY Diabetes Care; 2024 Oct; 47(10):1778-1786. PubMed ID: 39106206 [TBL] [Abstract][Full Text] [Related]
9. Switching to the Minimed™ 780G system achieves clinical targets for CGM in adults with type 1 diabetes regardless of previous insulin strategy and baseline glucose control. Lepore G; Rossini A; Bellante R; Corsi A; Scaranna C; Dodesini AR; Trevisan R Acta Diabetol; 2022 Oct; 59(10):1309-1315. PubMed ID: 35857108 [TBL] [Abstract][Full Text] [Related]
10. Glycemic Outcomes During Early Use of the MiniMed™ 780G Advanced Hybrid Closed-Loop System with Guardian™ 4 Sensor. Cordero TL; Dai Z; Arrieta A; Niu F; Vella M; Shin J; Rhinehart AS; McVean J; Lee SW; Slover RH; Forlenza GP; Shulman DI; Pop-Busui R; Thrasher JR; Kipnes MS; Christiansen MP; Buckingham BA; Pihoker C; Sherr JL; Kaiserman KB; Vigersky RA Diabetes Technol Ther; 2023 Sep; 25(9):652-658. PubMed ID: 37252734 [No Abstract] [Full Text] [Related]
11. Diabetes technology and treatments in the paediatric age group. Shalitin S; Peter Chase H Int J Clin Pract Suppl; 2011 Feb; (170):76-82. PubMed ID: 21323816 [TBL] [Abstract][Full Text] [Related]
12. Impact on Glycemia Risk Index and other metrics in type 1 adult patients switching to Advanced Hybrid Closed-Loop systems: a one-year real-life experience. Resmini E; Zarra E; Dotti S; Rotondi G; Cornaghi AV; Madaschi S; Cimino E; Massari G; Pezzaioli LC; Buoso C; Sandri M; Girelli A Eur J Med Res; 2024 Jul; 29(1):365. PubMed ID: 39004734 [TBL] [Abstract][Full Text] [Related]
13. No more hypoglycaemia on days with physical activity and unrestricted diet when using a closed-loop system for 12 weeks: A post hoc secondary analysis of the multicentre, randomized controlled Diabeloop WP7 trial. Franc S; Benhamou PY; Borot S; Chaillous L; Delemer B; Doron M; Guerci B; Hanaire H; Huneker E; Jeandidier N; Amadou C; Renard E; Reznik Y; Schaepelynck P; Simon C; Thivolet C; Thomas C; Hannaert P; Charpentier G Diabetes Obes Metab; 2021 Sep; 23(9):2170-2176. PubMed ID: 34009725 [TBL] [Abstract][Full Text] [Related]
14. Early Real-World Performance of the MiniMed™ 780G Advanced Hybrid Closed-Loop System and Recommended Settings Use in the United States. Thrasher JR; Arrieta A; Niu F; Cameron KR; Cordero TL; Shin J; Rhinehart AS; Vigersky RA Diabetes Technol Ther; 2024 Mar; 26(S3):24-31. PubMed ID: 38377317 [No Abstract] [Full Text] [Related]
15. Safety and Glycemic Outcomes During the MiniMed™ Advanced Hybrid Closed-Loop System Pivotal Trial in Adolescents and Adults with Type 1 Diabetes. Carlson AL; Sherr JL; Shulman DI; Garg SK; Pop-Busui R; Bode BW; Lilenquist DR; Brazg RL; Kaiserman KB; Kipnes MS; Thrasher JR; Reed JHC; Slover RH; Philis-Tsimikas A; Christiansen M; Grosman B; Roy A; Vella M; Jonkers RAM; Chen X; Shin J; Cordero TL; Lee SW; Rhinehart AS; Vigersky RA Diabetes Technol Ther; 2022 Mar; 24(3):178-189. PubMed ID: 34694909 [No Abstract] [Full Text] [Related]
16. Intermittent-scanned continuous glucose monitoring with low glucose alarms decreases hypoglycemia incidence in middle-aged adults with type 1 diabetes in real-life setting. Oriot P; Hermans MP J Diabetes Complications; 2023 Feb; 37(2):108385. PubMed ID: 36603333 [TBL] [Abstract][Full Text] [Related]
17. Closed-Loop Insulin Delivery Versus Sensor-Augmented Pump Therapy in Older Adults With Type 1 Diabetes (ORACL): A Randomized, Crossover Trial. McAuley SA; Trawley S; Vogrin S; Ward GM; Fourlanos S; Grills CA; Lee MH; Alipoor AM; O'Neal DN; O'Regan NA; Sundararajan V; Colman PG; MacIsaac RJ Diabetes Care; 2022 Feb; 45(2):381-390. PubMed ID: 34844995 [TBL] [Abstract][Full Text] [Related]
18. Hybrid closed-loop insulin delivery versus sensor-augmented pump therapy in children aged 6-12 years: a randomised, controlled, cross-over, non-inferiority trial. Kariyawasam D; Morin C; Casteels K; Le Tallec C; Sfez A; Godot C; Huneker E; Garrec N; Benhamou PY; Polak M; Charpentier G; Franc S; Beltrand J Lancet Digit Health; 2022 Mar; 4(3):e158-e168. PubMed ID: 35216750 [TBL] [Abstract][Full Text] [Related]
19. Hybrid Closed-Loop Control with Ultrarapid Lispro Compared with Standard Insulin Aspart and Faster Insulin Aspart: An In Silico Study. Lachal S; Tourki Y; Franc S; Huneker E; Charpentier G; Benhamou PY J Diabetes Sci Technol; 2023 Jan; 17(1):176-185. PubMed ID: 34658265 [TBL] [Abstract][Full Text] [Related]
20. The Medtronic 780G advanced hybrid closed-loop system achieves and maintains good glycaemic control in type 1 diabetes adults despite previous treatment. Quirós C; Alonso-Carril N; Rodríguez-Rodríguez S; Barahona MJ; Orois A; Simó-Servat A; Ramos M; Perea V Endocrinol Diabetes Nutr (Engl Ed); 2023 Feb; 70(2):130-135. PubMed ID: 36925230 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]